GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nevro Corp (NYSE:NVRO) » Definitions » Gross Profit

Nevro (NVRO) Gross Profit : $297.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Nevro Gross Profit?

Nevro's gross profit for the three months ended in Mar. 2024 was $71.5 Mil. Nevro's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $297.0 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Nevro's gross profit for the three months ended in Mar. 2024 was $71.5 Mil. Nevro's Revenue for the three months ended in Mar. 2024 was $101.9 Mil. Therefore, Nevro's Gross Margin % for the quarter that ended in Mar. 2024 was 70.19%.

Nevro had a gross margin of 70.19% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 12 years, the highest Gross Margin % of Nevro was 70.57%. The lowest was 59.60%. And the median was 68.49%.


Nevro Gross Profit Historical Data

The historical data trend for Nevro's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nevro Gross Profit Chart

Nevro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 268.35 249.90 266.04 276.37 290.06

Nevro Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.62 74.44 69.52 81.48 71.53

Competitive Comparison of Nevro's Gross Profit

For the Medical Devices subindustry, Nevro's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nevro's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nevro's Gross Profit distribution charts can be found below:

* The bar in red indicates where Nevro's Gross Profit falls into.



Nevro Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Nevro's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=425.174 - 135.114
=290.1

Nevro's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=101.899 - 30.371
=71.5

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $297.0 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Nevro's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=71.5 / 101.899
=70.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Nevro  (NYSE:NVRO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Nevro had a gross margin of 70.19% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Nevro Gross Profit Related Terms

Thank you for viewing the detailed overview of Nevro's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Nevro (NVRO) Business Description

Traded in Other Exchanges
Address
1800 Bridge Parkway, Redwood City, CA, USA, 94065
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
Executives
Greg Siller officer: Chief Commercial Officer C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Shawn Mccormick director 9600-54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55441
Kevin R Thornal officer: President & CEO 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Sridhar Kosaraju director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Richard B. Carter officer: Chief Accounting Officer C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Kashif Rashid officer: General Counsel C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
D Keith Grossman director, officer: President & CEO
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Michael F Demane director, officer: Chief Executive Officer MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Niamh Louise Pellegrini officer: Chief Commercial Officer C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Brad Vale director C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Susan E Siegel director 3000 SAND HILL ROAD, BLDG 3 STE 290, MENLO PARK CA 94025
Roderick H. Macleod officer: Chief Financial Officer C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Patrick Schmitz officer: Vice President, Operations C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065